Description du projet
Cibler les sous‑populations préexistantes de cellules cancéreuses ovariennes résistantes aux médicaments
Le cancer des ovaires est le cinquième type de cancer le plus meurtrier en Europe. La chimiothérapie standard est efficace pour éliminer les masses tumorales, mais la plupart des patientes auxquelles a été diagnostiqué un cancer des ovaires avancé décèdent après l’apparition de nouvelles lésions provenant de petites sous‑populations de cellules résistantes aux médicaments. Le projet RESIST3D, financé par l’UE, ouvre de nouvelles perspectives pour la médecine de précision dans le domaine du cancer en ciblant de petites sous‑populations préexistantes de cellules résistantes aux médicaments plutôt que la masse tumorale. La recherche utilise des organoïdes 3D issus de patientes atteintes de cancer des ovaires pour rechercher de nouvelles stratégies d’éradication des cellules cancéreuses résistantes aux médicaments. Les modèles de profilage de la réponse aux médicaments aideront à identifier le traitement qui éradiquera les cellules préexistantes résistantes aux médicaments et qui sera appliqué en combinaison avec la chimiothérapie standard.
Objectif
Ovarian cancer is the fifth most deadly cancer type among women in Europe. Despite the fact that standard chemotherapy is usually effective in eliminating bulk tumour mass, thereby inducing remission, most patients diagnosed with advanced ovarian cancer die from the disease, as relapsed lesions emerge from small subpopulations of surviving drug-resistant cells.
Precision medicine aims to improve cancer care through tailoring individualized therapies based on genomic or functional profiling of human cancers. However, as these approaches are usually performed on bulk tumour cells, the small pre-existing drug-resistant cell subpopulations remain untargeted.
In the RESIST3D project, I will utilize ovarian cancer organoids – a patient-derived, three-dimensional cell cultures – to search for new strategies to eradicate drug-resistant cancer cells. I will use two organoid models developed for the same patient – one model derived from tumour material taken before chemotherapeutic treatment and one from a post-treatment sample, typically enriched in drug-resistant cells. I will further enrich the organoids in quiescent, drug-resistant cells by maintaining them in physiologic-like culture medium. I will then apply the models for drug-response profiling in order to identify agents that eradicate pre-existing drug-resistant cells, which could be combined with standard chemotherapy. Finally, I will assess whether the selected combinations prevent relapses in patient-derived xenograft mouse models.
RESIST3D sets a new direction in precision cancer medicine, as it focuses on targeting small pre-existing subpopulations of drug-resistant cells rather than bulk tumour mass. Through combining organoid model, paired samples for each patient and physiologic culture conditions, I expect to identify new ways to target drug-resistant ovarian cancer cells. Moreover, RESIST3D will provide me with new research expertise and a scientific network that will enhance my research career.
Champ scientifique
Mots‑clés
Programme(s)
Régime de financement
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)Coordinateur
1165 Kobenhavn
Danemark